Menu Search
Equities

Haemonetics Corp

HAE:NYQ

Haemonetics Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)85.45
  • Today's Change0.02 / 0.02%
  • Shares traded33.72k
  • 1 Year change+4.23%
  • Beta0.3589
Data delayed at least 15 minutes, as of Nov 22 2024 15:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy3
Outperform5
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Haemonetics Corporation have a median target of 113.50, with a high estimate of 125.00 and a low estimate of 85.00. The median estimate represents a 32.86% increase from the last price of 85.43.
High46.3%125.00
Med32.9%113.50
Low-0.5%85.00

Dividends in USD

Historical dividend information is not available for Haemonetics Corp.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On Nov 07, 2024, Haemonetics Corporation reported 2nd quarter 2025 earnings of 1.12 per share. This result was in line with the consensus of the 10 analysts following the company and exceeded last year's 2nd quarter results by 13.13%.
The next earnings announcement is expected on Feb 06, 2025.
Average growth rate+3.68%
Haemonetics Corporation reported annual 2024 earnings of 3.96 per share on May 09, 2024.
Average growth rate+7.23%
More ▼

Revenue history & estimates in USD

Haemonetics Corporation had 2nd quarter 2025 revenues of 345.51m. This bettered the 342.65m consensus of the 10 analysts covering the company. This was 10.98% above the prior year's 2nd quarter results.
Average growth rate+2.12%
Haemonetics Corporation had revenues for the full year 2024 of 1.31bn. This was 12.01% above the prior year's results.
Average growth rate+7.96%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.